Search

Displaying results 3351 - 3360 of 8697 in total
  1. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115]. … [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]

  2. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. … To date, our scientists have shown that approximately 90% of patients studied with antibody-mediated thrombosis have antibodies that bind to this region.

  3. Drug

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine

    go.drugbank.com/drugs/DB14196
    Approved

    Sensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.

    Synonyms: N-Cyclohexyl-N'-phenyl-p-phenylendiamine, N-cyclohexyl-N'-phenyl-p-phenylenediamine
  4. Drug

    Bezafibrate

    go.drugbank.com/drugs/DB01393
    ApprovedInvestigational

    Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.

    Synonyms: 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acidCategories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  5. Drug

    Hydrocortisone phosphate

    go.drugbank.com/drugs/DB14542
    ApprovedInvestigationalVet approved

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inducers
  6. Drug

    Dronabinol

    go.drugbank.com/drugs/DB00470
    ApprovedIllicitInvestigational

    Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting … While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects.

    Categories: Cannabinoid Receptor Agonists, P-glycoprotein inhibitors
  7. Drug

    Orphenadrine

    go.drugbank.com/drugs/DB01173
    ApprovedInvestigational

    A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.

    Categories: NMDA Receptor Antagonists, Cytochrome P-450 Substrates
  8. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … centanafadine as the first and only approved norepinephrine-dopamine-serotonin reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  9. Drug

    Meningococcal polysaccharide vaccine group W-135

    go.drugbank.com/drugs/DB13887
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.

    Mixtures: MENVEO POWDER & SOLUTION FOR SOLUTION FOR INJECTION, Menveo Powder and Solution for Solution for Injection
  10. Drug

    Plecanatide

    go.drugbank.com/drugs/DB13170
    ApprovedInvestigational

    Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

    Categories: Drugs for Constipation